【要闻报道】 中美首轮谈判发布联合声明：90天关税暂停，中美经济重新审视互补性 中美在瑞士日内瓦举行经贸高层会谈，双方在经贸领域达成一系列重要共识。当地时间5月12日上午9： 00，双方发布《中美日内瓦经贸会谈联合声明》。 联合声明发布后，引发了金融市场强烈反应。富时中国A50指数期货一度涨超2%；离岸人民币兑美元 一度大涨超400点。美股三大期指亦快速拉高。与此同时，外资机构对中国资产的后市展望愈发乐观。 在中美日内瓦经贸会谈联合声明发布前夕，花旗银行报告称，假设中美就关税问题谈判取得进展，上调 恒生指数今年底目标价2%至25000点，并予明年上半年目标价26000点。 相关解读：中信建投解读中美会谈：2点超预期3大影响 牛弹琴：中美日内瓦会谈，最大亮点有三个 商务部：严打战略矿产走私出口，加大口岸查验和打击查处力度 今天，商务部新闻发言人就开展打击战略矿产走私出口专项行动应询答记者问。 问：我们注意到，近日国家出口管制工作协调机制办公室部署开展了打击战略矿产走私出口专项行动， 请问专项行动是出于什么考虑？还将开展哪些工作？ 答：加强战略矿产资源出口管制事关国家安全和发展利益。我们对部分战略矿产实施出口管制 ...

重要的消息有哪些 1.中美日内瓦经贸会谈联合声明 双方承诺将于2025年5月14日前采取以下举措：美国将（一）修改2025年4月2日第14257号行政令中规定的对中国商品（包括香港特别行政区和澳门特别行政 区商品）加征的从价关税，其中，24%的关税在初始的90天内暂停实施，同时保留按该行政令的规定对这些商品加征剩余10%的关税；（二）取消根据2025 年4月8日第14259号行政令和2025年4月9日第14266号行政令对这些商品的加征关税。中国将（一）相应修改税委会公告2025年第4号规定的对美国商品加征 的从价关税，其中，24%的关税在初始的90天内暂停实施，同时保留对这些商品加征剩余10%的关税，并取消根据税委会公告2025年第5号和第6号对这些商 品的加征关税；（二）采取必要措施，暂停或取消自2025年4月2日起针对美国的非关税反制措施。采取上述举措后，双方将建立机制，继续就经贸关系进行 协商。中方代表是国务院副总理何立峰，美方代表是财政部长斯科特·贝森特和美国贸易代表贾米森·格里尔。协商可在中国、美国，或双方商定的第三国进 行。根据需要，双方可就相关经贸议题开展工作层面磋商。 5.《关于金融支持广州 ...

Policy Developments - Heilongjiang Province has initiated a joint action among eight departments to regulate illegal medical advertisements, particularly targeting "miracle doctor" ads that mislead consumers by using false credentials or endorsements [2] Drug and Device Approvals - Merck announced the launch of its new antibiotic, Recarbrio® (Imipenem/Cilastatin/Relebactam), in China, which is indicated for treating infections caused by sensitive Gram-negative bacteria in patients aged 18 and older [4] Capital Markets - Jingtai Holdings plans to acquire 90% of Shanghai Siwei Medical Technology for a total consideration of 250 million yuan, enhancing its capabilities in AI healthcare and drug development [6] - Yihe Jiaye has signed a strategic cooperation framework agreement with Shenzhen Hanyu Pharmaceutical and Shenzhen Hanyu Health Technology to develop a sleep health ecosystem through resource integration [7] Industry Developments - Kintor Pharmaceutical released preliminary clinical data for its CT0596 CAR-T cell injection targeting BCMA, currently under exploration for treating relapsed/refractory multiple myeloma [9] - Hanyu Pharmaceutical has agreed to collaborate with Shenzhen Carbon Cloud Peptide Technology on the development of a novel peptide drug targeting GLP-1R/GIPR/GCGR, which currently has no similar products approved for market [10] - Eli Lilly's tirzepatide has shown superior weight loss efficacy compared to Novo Nordisk's semaglutide in a head-to-head clinical trial, potentially reshaping the obesity treatment market [11]

Company Announcements - Zhaowei Electromechanical plans to reduce its shareholding by no more than 1.5%, equating to approximately 3.6 million shares [1] - China CNR Corporation has signed several major contracts totaling approximately 54.74 billion yuan, representing about 22.2% of its expected revenue for 2024 [2] - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a temporary suspension of its stock [2] - Sunshine Nuohua intends to acquire 100% of Langyan Life, with its stock set to resume trading [3] - Wolong Materials is planning to issue H-shares and apply for a listing on the Hong Kong Stock Exchange [3] - Hanyu Pharmaceutical has signed a joint development agreement for a novel peptide drug targeting metabolic diseases [3] - Lijun Co. confirms that its operations are normal and there are no undisclosed significant matters [3] Investments & Acquisitions - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [4] - Shuangyi Technology intends to acquire 100% of Marky Industries for 18 million AUD, along with specific assets [5] Strategic Partnerships - Sileck has signed a strategic cooperation agreement with Lihua Power for the development of large cylindrical batteries [6] - Hongchang Technology plans to invest 15 million yuan in a humanoid robot industry chain company [7] - Macroview Technology is establishing a wholly-owned subsidiary focused on artificial intelligence [8] - Yihua Jiaye has signed a strategic cooperation framework agreement with Hanyu Pharmaceutical and Hanyu Health to develop a sleep health ecosystem [9] - Wanda Film is investing in Lezi Tiancheng and will engage in strategic cooperation in IP toy product development [10] Shareholding Changes - Tiandi Online's controlling shareholder is transferring 6.97% of its shares to introduce a strategic investor [12] - Longjiang Transportation plans to reduce its shareholding by no more than 3% [13] - Boyun New Materials intends to reduce its shareholding by no more than 3% [14] - Tongrun Equipment's major shareholder plans to reduce its stake by no more than 2% [15] Financing & Capital Increase - Tangyuan Electric plans to raise no more than 864 million yuan through a private placement [16] - Shangsheng Electronics intends to issue convertible bonds to raise up to 330 million yuan [17] Other Developments - Xianju Pharmaceutical has obtained a domestic production registration certificate for Dydrogesterone tablets [18] - Rongchang Bio has received a clinical trial application acceptance notice for its antibody-drug conjugate RC278 [19] - Jiangsu Leili's subsidiary Dingzhi Technology is implementing a stock incentive plan [20]

Group 1: Stock Suspension and Resumption - Sunshine Nuohuo plans to acquire 100% equity of Langyan Life Science, leading to stock resumption. Langyan Life focuses on high-end chemical drugs and APIs, having established a mature pharmaceutical production system over the years [1] - Yunnan Copper is planning to purchase 40% equity of Liangshan Mining, resulting in stock suspension [2] Group 2: Mergers and Acquisitions - China Pharmaceutical intends to acquire 100% equity of Jinsui Technology for 302 million yuan. Jinsui Technology specializes in e-commerce operations, covering personal health consumer products and has established partnerships with well-known brands like Philips and Omron [3] Group 3: Share Buybacks and Increases - Tianqiao Hoisting's controlling shareholder plans to increase holdings of the company's shares by 75 million to 150 million yuan [4] Group 4: Investment Cooperation and Business Status - Kute Intelligent is collaborating with Huawei to upgrade AI Agent 2.0, expected to be completed by 2025 [5] - Heng'erda has completed the signing of an acquisition agreement for the German grinding machine company SMS [6] - Hongchang Technology plans to invest 15 million yuan in Guangdong Liangzhi Joint Technology, focusing on the humanoid robot industry chain [6] - Hongjing Technology intends to establish a wholly-owned subsidiary, Shenzhen Digital Zongheng Technology Co., Ltd., with an investment of 10 million yuan, focusing on AI hardware sales and innovation services [6] - Hanyu Pharmaceutical has signed a joint development agreement for a GLP-1R/GIPR/GCGR triple agonist peptide innovative drug with Carbon Cloud Smart Peptide [7] - Longsheng Technology's project with Silis for new energy vehicle motor semi-assemblies is expected to start supplying in the second half of 2025 [8] - Yihe Jiaye has signed a strategic cooperation framework agreement with Hanyu Pharmaceutical and Hanyu Health to develop a sleep health ecosystem [8] - Nanjing Steel's wholly-owned subsidiary successfully bid for the exploration rights of Fanqiao Iron Mine for 920 million yuan [9] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation [10] - CRRC has signed major contracts totaling 54.74 billion yuan, accounting for 22.2% of the company's projected revenue for 2024 under Chinese accounting standards [11] - Sileck has signed a strategic cooperation agreement with Lihua Power for the 46 series large cylindrical batteries [12]

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-040 3、本协议不涉及具体交易安排及实质性业务往来，不构成关联交易，也不 构成重大资产重组，无需提交公司董事会和股东大会审议。 一、协议签署的基本情况 为充分发挥各方在睡眠健康领域的协同优势，北京怡和嘉业医疗科技股份有 限公司（以下简称"公司"）与深圳翰宇药业股份有限公司（以下简称"翰宇药 业"）、深圳翰宇健康科技有限公司（以下简称"翰宇健康"）于 2025 年 5 月 12 日共同签署了《战略合作框架协议》（以下简称"框架协议"）。基于三方在 技术研发、产品创新及渠道资源等方面的互补性，本次合作旨在整合优势资源， 构建"产品+器械"协同发展的睡眠健康生态系统，共同探索睡眠障碍预防、治 疗及健康管理的创新模式。通过联合品牌推广及市场拓展，实现互利共赢。 1 根据《深圳证券交易所创业板股票上市规则》及《北京怡和嘉业医疗科技股 份有限公司章程》的相关规定，本协议项下的交易属于公司的日常经营行为，不 构成《上市公司重大资产重组管理办法》规定的重大资产重组，签订本协议无需 提交公司董事会和股东大会审议。 二、合作方基本情况 本公司及董事会全体成员保证信 ...

怡和嘉业（301367）公告，公司与深圳翰宇药业（300199）股份有限公司、深圳翰宇健康科技有限公司 于2025年5月12日共同签署了《战略合作框架协议》。该协议旨在整合优势资源，构建"产品+器械"协同 发展的睡眠健康生态系统，共同探索睡眠障碍预防、治疗及健康管理的创新模式。协议自签字盖章之日 起生效，有效期五年。 ...

Group 1 - Public fund institutions remained active in research activities, with 146 institutions participating in A-share company research from May 5 to May 11, covering 156 stocks across 24 industries, totaling 1198 research instances [1][2] - The mechanical equipment sector stood out, with LeiSai Intelligent (002979) leading with 54 research instances, attracting nearly 30% of public institutions, while Honghua Digital Technology also received 33 instances [1][2] - The pharmaceutical and biological industry was another focus, with three stocks in the top ten, including Baiji Shenzhou, YiHe JiaYe (301367), and AoHua Endoscopy, receiving 49, 44, and 35 research instances respectively, indicating strong market interest in innovative drugs and medical devices [1][2] Group 2 - The electronic, pharmaceutical, and mechanical equipment sectors were the main areas of focus for public fund research, with electronic industry leading at 201 instances, followed by pharmaceutical at 194, and mechanical equipment at 143 [2] - A significant concentration of research activity was noted, with over 60% of public institutions conducting more than four research activities, and nine leading institutions exceeding 20 research instances [2][3] - Among the top ten active public institutions, Penghua Fund Management conducted 28 research instances, focusing on stocks like Naer Shares (002825), Oulutong (300870), and Honghua Digital Technology, which had notable weekly gains [3]

Core Viewpoint - Public fund institutions remain highly active in conducting research on A-share companies, with a total of 146 institutions participating in 1,198 research instances during the week of May 5 to May 11, 2025, covering 156 stocks across 24 primary industries [1]. Group 1: Top Stocks in Research - The top ten stocks with the highest research frequency include: - LeiHan Intelligent (54 times, +3.41%) - BeiGene (49 times, -6.76%) - YiHe JiaYe (44 times, +10.70%) - DeMingLi (37 times, -3.14%) - XiangXin Technology (36 times, +5.32%) - AoHua Endoscopy (35 times, +4.30%) - WenJian Medical (35 times, -1.47%) - HongHua Digital Science (33 times, +8.77%) - XingYe YinXi (31 times, -1.73%) - ZhouDaSheng (29 times, +0.77%) [2]. Group 2: Industry Focus - The mechanical equipment industry stands out with LeiHan Intelligent leading in research frequency, attracting nearly 30% of public institutions [2]. - The pharmaceutical and biotechnology sector is also a major focus, with BeiGene and YiHe JiaYe ranking second and third in research frequency, respectively [3]. - The electronic, pharmaceutical, and mechanical equipment sectors are the primary areas of interest for public fund research, with a total of 538 research instances, accounting for 44.91% of all public fund research activities [3].

Group 1 - The pharmaceutical sector is a key focus for institutional investors, with brokers increasing their investments and research efforts in this area [1] - As of the end of Q1, 14 brokerage firms were among the top ten shareholders of 25 pharmaceutical companies, holding a total of 508 million shares valued at 4.118 billion [1] - In Q1, brokers frequently adjusted their holdings in the pharmaceutical sector, initiating positions in 10 stocks, increasing holdings in 3, and reducing holdings in 11 [1][2] Group 2 - New positions taken by brokers in Q1 included 1.162 billion for Yihe Jiaye and 1.13 billion for Borui Pharmaceutical, with significant holdings also in Jia Ying Pharmaceutical and Chuangguang Medical [2] - Brokers have been actively conducting on-site research to gather firsthand information about the pharmaceutical sector, with over 50 brokers focusing on companies like Aibo Medical and Wanjian Medical [2] - A total of 23 pharmaceutical stocks have been recommended by brokers this month, with notable mentions including Baiji Shenzhou and Heng Rui Pharmaceutical, indicating strong long-term growth prospects [3] Group 3 - The pharmaceutical sector is expected to see a recovery in profitability by 2025, with current PE valuations at historical lows, suggesting potential for excess returns compared to the broader market [3] - Analysts recommend focusing on high-growth, strong recovery, and new expectations for pharmaceutical investments in 2025, particularly in innovative drugs and medical devices [4] - Investment strategies should prioritize companies with significant product advantages and healthy balance sheets, especially those with global sales potential [4]